Primary regulatory T cell in-vitro amplification system and method

An in vitro expansion and expansion system technology, which is applied in the in vitro expansion system and expansion field of primary regulatory T cells, can solve the problems of reducing the purity of regulatory T cells, residual T cells, and limited practical effects

Inactive Publication Date: 2020-02-28
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, the current in vitro culture of primary regulatory T cells still has the following problems: ① Regulatory T cells show immune incompetence in vitro, and it is difficult to expand with conventional culture medium, so it is necessary to add activating factors anti-CD3, CD28 antibodies (anti- CD3 / 28Ab) and interleukin-2 (IL-2) to stimulate cell proliferation; ②Immunomagnetic bead sorting method can obtain high-purity primary regulatory T cells, but there are still a small amount of effector T cells remaining. The secreted inflammatory factors will lead to down-regulation of the transcription factor Foxp3 expression of regulatory T cells, which will significantly reduce the purity of regulatory T cells in the expansion system; ③ Studies have shown that rapamycin (Rapamycin, Rapa) is a commonly used clinical immunosuppressant , can selectively inhibit the proliferation of effector T cells, which is beneficial to the expansion of regulatory T cells in vitro and the stable expression of Foxp3, but the actual effect is limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Primary regulatory T cell in-vitro amplification system and method
  • Primary regulatory T cell in-vitro amplification system and method
  • Primary regulatory T cell in-vitro amplification system and method

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0040] The preparation of preparation example 1 basal medium

[0041]In a sterile operating bench, add 10ml of fetal bovine serum, 1ml of 100* double antibody (penicillin + streptomycin), 11mg of sodium pyruvate, 3% glutamine (using a micrometer with a pore size of 0.22μm) to the 1640 medium (100ml). Pore ​​membrane filtration sterilization) 1ml, β-mercaptoethanol 0.39mg, fully shake and shake, and prepare the basal medium.

Embodiment 1

[0042] The preparation of embodiment 1 in vitro amplification system

[0043] On the basis of the basal medium obtained in Preparation Example 1, 0.2 mg of anti-CD3 / 28Ab (final concentration 2 μg / ml), 0.1 ml of mIL-2 (1 million units / ml) (final concentration 1000 U / ml), Rapa 10 μg (final concentration 100 ng / ml), TGF-β1 0.4 μg (final concentration 4 ng / ml), shake well, and make regulatory T cell in vitro expansion system.

Embodiment 2

[0044] The preparation of embodiment 2 in vitro amplification system

[0045] The preparation method and raw materials are as in Example 1, except that the amount of Rapa added is 15 μg, and the final concentration is 150 ng / ml, and the amount of TGF-β1 added is 0.5 μg, and the final concentration is 5 ng / ml.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a primary regulatory T cell in-vitro amplification system. The amplification system is prepared by adding anti-CD3/28 antibody, interleukin-2. Rapa and transforming growth factor-beta 1 into a basic culture medium, wherein the final concentration of the anti-CD3/28 antibody is 2 microgram/ml, the final concentration of the interleukin-2 is 1000U/ml, the final concentrationof the Rapa is 100-200 nanogram/ml, and the final concentration of the transforming growth factor-beta 1 is 4-8 nanogram/ml. Compared with an amplification system which uses the Rapa alone, the Rapa and transforming growth factor-beta 1 combined amplification system is good in stability and high in Foxp3+regulatory T cell purity.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to an in vitro expansion system and expansion method of primary regulatory T cells. Background technique [0002] CD4 + CD25 + Regulatory T cells (Tregs) are the most important immunosuppressive cells in the body, which can effectively suppress immune responses and regulate immune balance. Their research and application in the fields of transplant tolerance induction and autoimmune disease treatment are widely focus on. [0003] In 1995, Sakaguchi et al. found that mice lacked CD4 + CD25 + Regulatory T cells can trigger a variety of autoimmune diseases, and the reinfusion of these regulatory T cells can inhibit the occurrence of diseases. Regulatory T cell subsets are developed and differentiated in the thymus or peripheral CD4+ naive T cells, and can inhibit the proliferation and differentiation of effector T cells through direct cell-to-cell contact, secretion...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/0783
CPCC12N5/0637C12N2501/15C12N2501/2302C12N2501/51C12N2501/515
Inventor 龙丹陈雪璐周彦妮李幼平李胜富
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products